Tumor Microenvironment-Responsive Biomimetic Self-Assembled Nanomedicine for Precision Combination Therapy against Triple-Negative Breast Cancer
ACS Applied Bio Materials · 03.08.2026 · 9 (15) · 7053-7068
DOI: 10.1021/acsabm.6c00693 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Applied Bio Materials, online erschienen am 20.07.2026. Verfasst von Qian Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Anhui Medical University, Hefei230032, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Nanomedicine, Biomimetic Materials, Antineoplastic Agents. Die Arbeit nennt 46 Literaturangaben. Gefördert von: Anhui Medical University, Natural Science Foundation of Anhui Province, Excellent Young Scientists Fund.
Abstract (Originalsprache)
Although strategic combination of cuproptosis and chemotherapy is emerging as a promising strategy against triple-negative breast cancer (TNBC), current drug delivery systems remain considerable challenges in achieving co-delivery of different formulas, such as complex nanocarrier design, limited drug loading capacity, and insufficient tumor targeting. Herein, cancer cell membrane-camouflaged, self-assembled nanoparticles (DCM@CCM) were fabricated for precision combination therapy against TNBC. In the strategy, the carrier-free self-assembled nanoparticles were one-pot fabricated by co-assembling copper ions (Cu2+), doxorubicin (DOX), and methotrexate (MTX) via hydrogen bonds, π−π stacking and metal-ligand coordination effect, followed by in situ camouflaging with cancer cell membranes. Benefiting from the homologous targeting effect, the developed DCM@CCM could specifically target tumor cells, promoting their cellular uptake. Following internalization into tumor cells, the DCM@CCM disassembled in response to a weakly acidic tumor microenvironment, releasing Cu2+, DOX, and MTX. Importantly, the Cu2+ was reduced to Cu+ by depleting intracellular glutathione, which not only activated cuproptosis but also catalyzed the endogenous hydrogen peroxide into highly toxic hydroxyl radicals via a Fenton-like reaction, resulting in mitochondrial dysfunction. Simultaneously, both DOX and MTX disrupted DNA synthesis to trigger cell apoptosis. Both in vitro and in vivo experiments indicated that DCM@CCM exhibited potent cytotoxicity against TNBC cells and effectively suppressed tumor growth in heterotopic tumor models with minimal side effects. Overall, our study not only provides a promising strategy for precision combination therapy against TNBC but also expands insight for developing nanoscale self-assembly-enabled nanomedicine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Anhui Medical University, Hefei230032, China.
- Anhui Provincial Key Laboratory of Oral Diseases Research, Stomatologic Hospital & College, Anhui Medical University, Hefei230032, China.
ORCID-Profile: Qunlin Zhang, Haifeng Lu
Förderung
- Anhui Medical University
- Natural Science Foundation of Anhui Province
- Excellent Young Scientists Fund
Zitieren
APA
Liu, Q., Tao, X., Luo, Y., Sheng, T., Xu, W., Zhang, Q., & Lu, H. (2026). Tumor Microenvironment-Responsive Biomimetic Self-Assembled Nanomedicine for Precision Combination Therapy against Triple-Negative Breast Cancer. ACS Applied Bio Materials, 9(15), 7053-7068. https://doi.org/10.1021/acsabm.6c00693
Vancouver
Liu Q, Tao X, Luo Y, Sheng T, Xu W, Zhang Q, et al. Tumor Microenvironment-Responsive Biomimetic Self-Assembled Nanomedicine for Precision Combination Therapy against Triple-Negative Breast Cancer. ACS Applied Bio Materials. 2026;9(15):7053-7068. doi:10.1021/acsabm.6c00693
BibTeX
@article{Liu2026,
author = {Liu, Qian and Tao, Xinyi and Luo, Yawen and Sheng, Ting and Xu, Wenhua and Zhang, Qunlin and Lu, Haifeng},
title = {Tumor Microenvironment-Responsive Biomimetic Self-Assembled Nanomedicine for Precision Combination Therapy against Triple-Negative Breast Cancer},
journal = {ACS Applied Bio Materials},
year = {2026},
volume = {9},
number = {15},
pages = {7053--7068},
doi = {10.1021/acsabm.6c00693}
}
EUVIMED